To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Bain Capital leads $215m Series D funding in Atea Pharmaceuticals, which is developing a covid-19 drug
Other investors in the funding included RA Capital Management, Perceptive Advisors, Rock Springs Capital, Adage Capital Management, T. Rowe Price, Redmile Group and Omega Funds. Existing investors are also participating, including Morningside Ventures, Cormorant Asset Management, Ally Bridge Group and Sectoral Asset Management.
